Drugs / WTX-212C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07556653 | Jun 2026 → Apr 2027 expected | cancer | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WTX-212C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07556653 ↗ |
| Modality | Cell therapy | “allogeneic engineered red blood cell-based injectable product” NCT07556653 ↗ |
| Route | Intravenous | “administered intravenously” NCT07556653 ↗ |